|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim J and Munster PN: Estrogens and breast
cancer. Ann Oncol. 36:134–148. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen F, Wang L, Feng Y, Ma W, Liu J, Bi Q,
Song Y, Gao R and Jia Y: F-box and leucine-rich repeat protein 16
controls tamoxifen sensitivity via regulation of mitochondrial
respiration in estrogen receptor-positive breast cancer cells. Hum
Cell. 36:2087–2098. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanker AB, Sudhan DR and Arteaga CL:
Overcoming endocrine resistance in breast cancer. Cancer Cell.
37:496–513. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kazi M, Alqahtani A, Alharbi M, Ahmad A,
Hussain MD, Alothaid H and Aldughaim MS: The development and
optimization of lipid-based self-nanoemulsifying drug delivery
systems for the intravenous delivery of propofol. Molecules.
28:14922023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun P, Huang H, Ma JC, Feng B, Zhang Y,
Qin G, Zeng W and Cui ZK: Repurposing propofol for breast cancer
therapy through promoting apoptosis and arresting cell cycle. Oncol
Rep. 52:1552024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Yu P, Bian L, Huang W, Li N and
Ye F: Survival benefits of propofol-based versus inhalational
anesthesia in non-metastatic breast cancer patients: a
comprehensive meta-analysis. Sci Rep. 14:163542024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tian D, Tian M, Ma ZM, Zhang LL, Cui YF
and Li JL: Anesthetic propofol epigenetically regulates breast
cancer trastuzumab resistance through IL-6/miR-149-5p axis. Sci
Rep. 10:88582020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Müller MR, Burmeister A, Skowron MA,
Stephan A, Bremmer F, Wakileh GA, Petzsch P, Köhrer K, Albers P and
Nettersheim D: Therapeutical interference with the epigenetic
landscape of germ cell tumors: A comparative drug study and new
mechanistical insights. Clin Epigenetics. 14:52022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moon S, Kim HJ, Lee Y, Lee YJ, Jung S, Lee
JS, Hahn SH, Kim K, Roh JY and Nam S: Oncogenic signaling pathways
and hallmarks of cancer in Korean patients with acral melanoma.
Comput Biol Med. 154:1066022023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang J, Liu F, Guo W, Bi X, Yuan S,
Shayiti F, Pan T, Li K and Chen P: Single-cell transcriptome
sequencing reveals aberrantly activated inter-tumor cell signaling
pathways in the development of clear cell renal cell carcinoma. J
Transl Med. 22:372024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Salvati A, Melone V, Sellitto A, Rizzo F,
Tarallo R, Nyman TA, Giurato G, Nassa G and Weisz A: Combinatorial
targeting of a chromatin complex comprising Dot1L, menin and the
tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of
endocrine therapy-resistant breast cancer. Breast Cancer Res.
24:522022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang S, Bei Y, Tian Q, He J, Wang R, Wang
Q, Sun L, Ke J, Xie C and Shen P: PFKFB4 facilitates palbociclib
resistance in oestrogen receptor-positive breast cancer by
enhancing stemness. Cell Prolif. 56:e133372023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu Y, Zhang H, Pan C, He G, Cui X, Yu X,
Zhang X, Wu D, Yang J, Wu X, et al: Integrated tumor genomic and
immune microenvironment analysis identifies predictive biomarkers
associated with the efficacy of neoadjuvant therapy for
triple-negative breast cancer. Cancer Med. 12:5846–5858. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li R, Ferdinand JR, Loudon KW, Bowyer GS,
Laidlaw S, Muyas F, Mamanova L, Neves JB, Bolt L, Fasouli ES, et
al: Mapping single-cell transcriptomes in the intra-tumoral and
associated territories of kidney cancer. Cancer Cell.
40:1583–1599.e1510. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shimizu H and Nakayama KI: A 23 gene-based
molecular prognostic score precisely predicts overall survival of
breast cancer patients. EBioMedicine. 46:150–159. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xue Y, Lian W, Zhi J, Yang W, Li Q, Guo X,
Gao J, Qu H, Lin W, Li Z, et al: HDAC5-mediated deacetylation and
nuclear localisation of SOX9 is critical for tamoxifen resistance
in breast cancer. Br J Cancer. 121:1039–1049. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lü M, Ding K, Zhang G, Yin M, Yao G, Tian
H, Lian J, Liu L, Liang M, Zhu T and Sun F: MicroRNA-320a
sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by
targeting ARPP-19 and ERRγ. Sci Rep. 5:87352015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yao J, Deng K, Huang J, Zeng R and Zuo J:
Progress in the understanding of the mechanism of tamoxifen
resistance in breast cancer. Front Pharmacol. 11:5929122020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leslie EM, Deeley RG and Cole SP:
Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2,
and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol.
204:216–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu H, Wang N, Yang R, Luan J, Cao M, Zhai
C, Wang S, Wei M, Wang D, Qiao J, et al: E3 ubiquitin ligase NEDD4L
negatively regulates skin tumorigenesis by inhibiting IL-6/GP130
signaling pathway. J Invest Dermatol. 144:2453–2464.e2411. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yin R, Gao J and Liu Y: Mechanisms
analysis for formononetin counteracted-osimertinib resistance in
non-small cell lung cancer cells: From the insight into the gene
transcriptional level. Chem Biol Drug Des. 103:e144352024.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Z, Gerstein M and Snyder M: RNA-Seq:
A revolutionary tool for transcriptomics. Nat Rev Genet. 10:57–63.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Angus L, Smid M, Wilting SM, Bos MK,
Steeghs N, Konings I, Tjan-Heijnen VCG, van Riel J, van de Wouw AJ,
Cpct C, et al: Genomic alterations associated with estrogen
receptor pathway activity in metastatic breast cancer have a
differential impact on downstream ER signaling. Cancers (Basel).
15:44162023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sasada S, Kondo N, Hashimoto H, Takahashi
Y, Terata K, Kida K, Sagara Y, Ueno T, Anan K, Suto A, et al:
Prognostic impact of adjuvant endocrine therapy for estrogen
receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Breast
Cancer Res Treat. 202:473–483. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barathan M, Vellasamy KM, Ibrahim ZA,
Mariappan V, Hoong SM and Vadivelu J: Zerumbone mediates apoptosis
and induces secretion of proinflammatory cytokines in breast
carcinoma cell culture. Iran J Basic Med Sci. 24:1538–1545.
2021.PubMed/NCBI
|
|
28
|
Icard P, Shulman S, Farhat D, Steyaert JM,
Alifano M and Lincet H: How the Warburg effect supports
aggressiveness and drug resistance of cancer cells? Drug Resist
Updat. 38:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kowsari H, Davoodvandi A, Dashti F,
Mirazimi SMA, Bahabadi ZR, Aschner M, Sahebkar A, Gilasi HR,
Hamblin MR and Mirzaei H: Resveratrol in cancer treatment with a
focus on breast cancer. Curr Mol Pharmacol. 16:346–361. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rasoolnezhad M, Safaralizadeh R,
Hosseinpour Feizi MA, Banan-Khojasteh SM, Roshani Asl E, Lotfinejad
P and Baradaran B: MiR-138-5p improves the chemosensitivity of
MDA-MB-231 breast cancer cell line to paclitaxel. Mol Biol Rep.
50:8407–8420. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun C, Liu P, Pei L, Zhao M and Huang Y:
Propofol inhibits proliferation and augments the anti-tumor effect
of doxorubicin and paclitaxel partly through promoting ferroptosis
in triple-negative breast cancer cells. Front Oncol. 12:8379742022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H, Zhao L, Wu J, Hong J and Wang S:
Propofol induces ROS-mediated intrinsic apoptosis and migration in
triple-negative breast cancer cells. Oncol Lett. 20:810–816. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang X, Li F, Zheng Y, Wang X, Wang K, Yu
Y and Zhao H: Propofol reduced mammosphere formation of breast
cancer stem cells via pd-l1/nanog in vitro. Oxid Med Cell Longev.
2019:90782092019.PubMed/NCBI
|
|
34
|
Malekmohammadi M, Price CM, Hudson AE,
DiCesare JAT and Pouratian N: Propofol-induced loss of
consciousness is associated with a decrease in thalamocortical
connectivity in humans. Brain. 142:2288–2302. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wakai A, Blackburn C, McCabe A, Reece E,
O'Connor G, Glasheen J, Staunton P, Cronin J, Sampson C, McCoy SC,
et al: The use of propofol for procedural sedation in emergency
departments. Cochrane Database Syst Rev.
2015:CD0073992015.PubMed/NCBI
|
|
36
|
Yoon S, Jung SY, Kim MS, Yoon D, Cho Y and
Jeon Y: Impact of propofol-based total intravenous anesthesia
versus inhalation anesthesia on long-term survival after cancer
surgery in a nationwide cohort. Ann Surg. 278:1024–1031. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Faienza F, Polverino F, Rajendraprasad G,
Milletti G, Hu Z, Colella B, Gargano D, Strappazzon F, Rizza S,
Vistesen MV, et al: AMBRA1 phosphorylation by CDK1 and PLK1
regulates mitotic spindle orientation. Cell Mol Life Sci.
80:2512023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Milletti G, Colicchia V and Cecconi F:
Cyclers' kinases in cell division: From molecules to cancer
therapy. Cell Death Differ. 30:2035–2052. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Decker T, Lüdtke-Heckenkamp K, Melnichuk
L, Hirmas N, Lübbe K, Zahn MO, Schmidt M, Denkert C, Lorenz R,
Müller V, et al: Anti-hormonal maintenance treatment with the
CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone
receptor positive / HER2 negative metastatic breast cancer: A phase
II trial (AMICA). Breast. 72:1035752023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ergun Y, Dogan M, Ucar G, Karacin P and
Karacin C: Efficacy of adjuvant CDK4/6 inhibitors in hormone
receptor-positive breast cancer: A systematic review and
meta-analysis. Expert Opin Pharmacother. 24:1901–1909. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Q, Jiang B, Guo J, Shao H, Del Priore
IS, Chang Q, Kudo R, Li Z, Razavi P, Liu B, et al: INK4 tumor
suppressor proteins mediate resistance to CDK4/6 kinase inhibitors.
Cancer Discov. 12:356–371. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pandey K, An HJ, Kim SK, Lee SA, Kim S,
Lim SM, Kim GM, Sohn J and Moon YW: Molecular mechanisms of
resistance to CDK4/6 inhibitors in breast cancer: A review. Int J
Cancer. 145:1179–1188. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Paternot S, Bockstaele L, Bisteau X,
Kooken H, Coulonval K and Roger PP: Rb inactivation in cell cycle
and cancer: The puzzle of highly regulated activating
phosphorylation of CDK4 versus constitutively active CDK-activating
kinase. Cell Cycle. 9:689–699. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Herrera-Abreu MT, Palafox M, Asghar U,
Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M,
Rodriguez O, Grueso J, et al: Early adaptation and acquired
resistance to CDK4/6 inhibition in estrogen receptor-positive
breast cancer. Cancer Res. 76:2301–2013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mihály Z, Kormos M, Lánczky A, Dank M,
Budczies J, Szász MA and Győrffy B: A meta-analysis of gene
expression-based biomarkers predicting outcome after tamoxifen
treatment in breast cancer. Breast Cancer Res Treat. 140:219–232.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu X, Sun A, Yu W, Hong C and Liu Z:
CXCL10 mediates breast cancer tamoxifen resistance and promotes
estrogen-dependent and independent proliferation. Mol Cell
Endocrinol. 512:1108662020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cao Z, Jin Z, Zeng L, He H, Chen Q, Zou Q,
Ouyang D, Luo N, Zhang Y, Yuan Y and Yi W: Prognostic and
tumor-immune infiltration cell signatures in tamoxifen-resistant
breast cancers. Gland Surg. 10:2766–2779. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gonçalves TL, de Araújo LP and Pereira
Ferrer V: Tamoxifen as a modulator of CXCL12-CXCR4-CXCR7 chemokine
axis: A breast cancer and glioblastoma view. Cytokine.
170:1563442023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Abdul-Sater AA, Edilova MI, Clouthier DL,
Mbanwi A, Kremmer E and Watts TH: The signaling adaptor TRAF1
negatively regulates toll-like receptor signaling and this
underlies its role in rheumatic disease. Nat Immunol. 18:26–35.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee HJ, Lee JJ, Song IH, Park IA, Kang J,
Yu JH, Ahn JH and Gong G: Prognostic and predictive value of
NanoString-based immune-related gene signatures in a neoadjuvant
setting of triple-negative breast cancer: Relationship to
tumor-infiltrating lymphocytes. Breast Cancer Res Treat.
151:619–627. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Weng L, Ziliak D, Lacroix B, Geeleher P
and Huang RS: Integrative ‘omic’ analysis for tamoxifen sensitivity
through cell based models. PLoS One. 9:e934202014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiang C, Zhu Y, Chen H, Lin J, Xie R, Li
W, Xue J, Chen L, Chen X and Xu S: Targeting c-Jun inhibits fatty
acid oxidation to overcome tamoxifen resistance in estrogen
receptor-positive breast cancer. Cell Death Dis. 14:6532023.
View Article : Google Scholar : PubMed/NCBI
|
